GPC1 and pancreatic neoplasm: A recent study by Melo et al. demonstrated the clinical utility of Glypican-1 (GPC1) on pancreatic cancer exosomes and the levels of Glypican 1 expressing exosomes (GPC1+ve exosomes) to be extremely capable of identifying early- and late-stage pancreatic cancer from healthy individuals or patients with BPD (AUC=1.0) [20].